MINNEAPOLIS, MINNESOTA -- (Marketwired) -- 12/20/13 -- DiaMedica Inc. (TSX VENTURE: DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual General and Special Meeting (the "Meeting") of shareholders of DiaMedica held on December 16, 2013, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were re-elected as the board of directors of DiaMedica.
In addition to the election of directors, the shareholders passed all resolutions placed before the Meeting as outlined in the management information circular dated November 6, 2013, including re-appointment of KPMG LLP, Chartered Accountants, as auditors for the upcoming year and authorizing the board of directors of DiaMedica at its discretion to amend the Articles of Incorporation of DiaMedica to consolidate the outstanding common shares of DiaMedica at a future date on the basis of one pre-consolidation common share for each two to five post-consolidation common share as more particularly described in the management information circular.
About DiaMedica
DiaMedica Inc. (TSX VENTURE: DMA) is a biotechnology company developing first-in-class treatments for the treatment of diabetes. DiaMedica's lead compound, DM199, is a recombinant human protein for the treatment of both Type 1 and Type 2 diabetes and their complications. The Company is also developing the first therapeutic GPCR agonist monoclonal antibody, DM204, for the treatment of Type 2 diabetes and cardiovascular disease. DiaMedica's shares trade on the TSX Venture Exchange (TSX VENTURE: DMA). For more information please visit www.diamedica.com.
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this News Release.
Contacts:
DiaMedica
Rick Pauls
President and CEO
763-710-4455
info@diamedica.com
DiaMedica
One Carlson Parkway, Suite 124
Minneapolis, MN
www.diamedica.com
